Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate

Executive Summary

With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.

Advertisement

Related Content

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study
Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel